2-amino-N-(4-(5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide,
AR-12 compound,
OSU 03012,
OSU-03012,
OSU-03012,
742112-33-0,
AR-12,
OSU 03012,
OSU-03012 (AR-12),
OSU03012,
PDK1 inhibitor AR-12,
2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide,
UNII-EX3O2Q61UV,
AR 12,
EX3O2Q61UV,
2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide,
CHEMBL1650595,
2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide,
PubChem22592,
MLS006010170,
SCHEMBL570472,
GTPL8005,
C26H19F3N4O,
DTXSID50225206,
EX-A253,
CHEBI:131196,
BCPP000134,
HMS3654O21,
BCP01835,
ZINC3960083,
ABP000481,
BDBM50430630,
MFCD12912272,
s1106,
AKOS025117573,
BCP9001039,
CS-0151,
RL04816,
RL04817,
SB16557,
1,2-Ethanediamine, N-(4-(5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-,
N-(4-(5-(2-Phenanthryl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)ethane-1,2-diamine,
OSU-03012/OSU03012,
NCGC00346490-01,
NCGC00346490-05,
4CA-0952,
AC-30302,
AK322519,
AS-19550,
BC660159,
HY-10547,
SC-85937,
SMR004701278,
FT-0721533,
SW219927-1,
Y0267,
EC-000.2346,
W-5543,
US8741944, 70,
BRD-K90497590-001-02-6,
OSU03012, OSU 03012, 742112-33-0,
OSU-03012|742112-33-0|OSU03012|OSU 03012,
2-amino-N-[4-[5-(2-phenanthryl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide,
2-amino-n-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-phenyl} acetamide,
2-Amino-N-{4-[5-(2-phenanthryl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide,
2-amino-N-{4-[5-(phenanthren-2-yl)-3-(trifluoromethyl)pyrazol-1-yl]phenyl}acetamide,
N-{4-[5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}glycinamide,
AR-12 compound,
cc-115,
D0C9JJ,
D0O1IM,
CID10027278,
A2846,
A10681,
3-[(tert-butyldimethylsilyl)oxy]cyclopentan-1-ol,
C500894,
2-amino-N-(4-(5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide,